Incyte Buys Vega Therapeutics for Up to $2 Billion to Bring New Once-a-Month Shot for Bleeding Disorder

Incyte is buying Vega Therapeutics to add VGA039 — a new once-monthly under-the-skin injection for von Willebrand disease (VWD).